Horng-Shiuann Wu1, Janet K Harden. 1. Author Affiliation: College of Nursing, Wayne State University, Detroit, Michigan.
Abstract
BACKGROUND: Cancer has a great impact on the well-being of affected persons and their caregivers long into survivorship. OBJECTIVE: This article reviews the state of science on the survivorship experience of cancer survivors and caregivers, with a focus on symptom burden and quality of life (QOL) after treatment termination. METHODS: The primary databases utilized included PubMed and CINAHL. Search results were limited to human participants, English language, and publications from 2008 to 2013. The articles retrieved included studies of prostate, breast, colorectal, and gynecologic cancers during adulthood. RESULTS: As many as a third of cancer survivors experienced symptoms after treatment cessation equivalent to those experienced during treatment. Fatigue, depression or mood disturbance, sleep disruption, pain, and cognitive limitation were commonly reported by survivors across various malignancies; depression, anxiety, and sleep disturbance affected some caregivers. The studies indicated residual symptoms that extend into survivorship have a great impact on QOL and are associated with disability and healthcare utilization. Younger age, lower socioeconomic status, and increased comorbidities are associated with poorer QOL and higher symptom distress in cancer survivors. Younger age and lower income are associated with greater distress and poorer QOL in caregivers. CONCLUSIONS: Survivors and caregivers struggle with symptom burden and diminished QOL long into survivorship. Longitudinal studies are needed to investigate the persistence and severity of symptom burden over time as well as long-term and late effects of these symptoms. IMPLICATIONS FOR PRACTICE: Interventions designed to help alleviate symptom burden in those most affected are needed.
BACKGROUND:Cancer has a great impact on the well-being of affected persons and their caregivers long into survivorship. OBJECTIVE: This article reviews the state of science on the survivorship experience of cancer survivors and caregivers, with a focus on symptom burden and quality of life (QOL) after treatment termination. METHODS: The primary databases utilized included PubMed and CINAHL. Search results were limited to humanparticipants, English language, and publications from 2008 to 2013. The articles retrieved included studies of prostate, breast, colorectal, and gynecologic cancers during adulthood. RESULTS: As many as a third of cancer survivors experienced symptoms after treatment cessation equivalent to those experienced during treatment. Fatigue, depression or mood disturbance, sleep disruption, pain, and cognitive limitation were commonly reported by survivors across various malignancies; depression, anxiety, and sleep disturbance affected some caregivers. The studies indicated residual symptoms that extend into survivorship have a great impact on QOL and are associated with disability and healthcare utilization. Younger age, lower socioeconomic status, and increased comorbidities are associated with poorer QOL and higher symptom distress in cancer survivors. Younger age and lower income are associated with greater distress and poorer QOL in caregivers. CONCLUSIONS: Survivors and caregivers struggle with symptom burden and diminished QOL long into survivorship. Longitudinal studies are needed to investigate the persistence and severity of symptom burden over time as well as long-term and late effects of these symptoms. IMPLICATIONS FOR PRACTICE: Interventions designed to help alleviate symptom burden in those most affected are needed.
Authors: Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed Journal: Cancer Date: 2019-04-01 Impact factor: 6.860
Authors: Martijn J L Bours; Bernadette W A van der Linden; Renate M Winkels; Fränzel J van Duijnhoven; Floortje Mols; Eline H van Roekel; Ellen Kampman; Sandra Beijer; Matty P Weijenberg Journal: Oncologist Date: 2016-02-24
Authors: Cecile A Lengacher; Richard R Reich; Carly L Paterson; Sophia Ramesar; Jong Y Park; Carissa Alinat; Versie Johnson-Mallard; Manolete Moscoso; Pinky Budhrani-Shani; Branko Miladinovic; Paul B Jacobsen; Charles E Cox; Matthew Goodman; Kevin E Kip Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Maria Antonietta Annunziata; Barbara Muzzatti; Cristiana Flaiban; Katiuscia Gipponi; Carlo Carnaghi; Paolo Tralongo; Michele Caruso; Raffaele Cavina; Umberto Tirelli Journal: Support Care Cancer Date: 2017-09-16 Impact factor: 3.603
Authors: N Fridriksdottir; S Gunnarsdottir; S Zoëga; B Ingadottir; E J G Hafsteinsdottir Journal: Support Care Cancer Date: 2017-09-18 Impact factor: 3.603
Authors: Mary Playdon; Leah M Ferrucci; Ruth McCorkle; Kevin D Stein; Rachel Cannady; Tara Sanft; Brenda Cartmel Journal: J Cancer Surviv Date: 2016-01-07 Impact factor: 4.442